In conclusion, to the best of our knowledge,
this Proteasome inhibitor is the first report where we have put forth an evidence of potential role of SPAG9 in cellular growth, migration, invasion and colony forming ability in highly aggressive triple-negative MDA-MB-231 JNK-IN-8 mw breast cancer cells. Furthermore we also demonstrated that SPAG9 expression was higher in all breast cancer cell compared to normal mammary epithelial cells. In addition, in vivo xenograft studies further strengthen the role of SPAG9 in breast cancer. Our study provides an association between SPAG9 expression and its potential role in breast cancer, and thus lays a foundation for developing a promising therapeutic target for triple-negative breast cancer. Acknowledgements This work is supported by grants from Indo-UK Cancer Research Program, Centre for Molecular Medicine, NII-core funding, Department of Biotechnology, Government of India. We also thank technical support by Mrs. Rekha Rani, National Institute of Immunology, New Delhi, India for confocal microscopy. References 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Canc J Clin 2011, Selleck Milciclib 61:69–90.CrossRef 2. Albertson DG, Collins C, McCormick F, Gray JW: Chromosome aberrations in solid tumors. Nat Genet 2003, 34:369–376.PubMedCrossRef
3. Jones PA: Overview of cancer epigenetics. Semin Hematol 2005,42(3 Suppl 2):S3-S8.PubMedCrossRef 4. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57–70.PubMedCrossRef 5. Bush NJ: Advances in hormonal therapy for breast cancer.
Semin Oncol Nurs 2007, 23:46–54.PubMedCrossRef 6. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39–51.PubMedCrossRef 7. Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM: Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Canc Res 2002, 14:R79.CrossRef 8. Tanja BC, Giulio S, Antonio J, Jasminka JR, Paula P, Nera S: High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. Med Oncol 2012, 29:1586–1591.PubMedCrossRef 9. Suri Liothyronine Sodium A, Saini S, Sinha A, et al.: Cancer testis antigens: A new paradigm for cancer therapy. OncoImmunology 2012, 1:1–3.CrossRef 10. Simpson AJG, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Canc 2005, 5:615–625.CrossRef 11. Garg M, Kanojia D, Khosla A, et al.: Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma. Canc Res 2008, 68:8240–8248.CrossRef 12. Garg M, Kanojia D, Suri S, Suri A: Small interfering RNA-mediated down-regulation of SPAG9 inhibits cervical tumor growth. Cancer 2009, 115:5688–5699.PubMedCrossRef 13.